Your activity: 122 p.v.
your limit has been reached. plz Donate us to allow your ip full access, Email: sshnevis@outlook.com

Society guideline links: Ovarian, fallopian tube, and peritoneal cancer

Society guideline links: Ovarian, fallopian tube, and peritoneal cancer

Introduction — This topic includes links to society and government-sponsored guidelines from selected countries and regions around the world. We will update these links periodically; newer versions of some guidelines may be available on each society's website. Some societies may require users to log in to access their guidelines.

The recommendations in the following guidelines may vary from those that appear in UpToDate topic reviews. Readers who are looking for UpToDate topic reviews should use the UpToDate search box to find the relevant content.

Links to related guidelines are provided separately. (See "Society guideline links: Ovarian and fallopian tube disease" and "Society guideline links: Screening for ovarian cancer" and "Society guideline links: Hereditary breast and ovarian cancer".)

International

Enhanced Recovery After Surgery (ERAS): Guidelines for perioperative care in cytoreductive surgery (CRS) with or without hyperthermic intraperitoneal chemotherapy (HIPEC) – Society recommendations: Part I – Preoperative and intraoperative management (2020)

ERAS: Guidelines for perioperative care in cytoreductive surgery (CRS) with or without hyperthermic intraperitoneal chemotherapy (HIPEC) – Society Recommendations: Part II – Postoperative management and special considerations (2020)

International Federation of Gynecology and Obstetrics (FIGO): Cancer report – Cancer of the ovary, fallopian tube, and peritoneum (2018)

International Collaboration on Cancer Reporting (ICCR): Recommendations – Data set for reporting of ovary, fallopian tube, and primary peritoneal carcinoma (2015)

Canada

Cancer Care Ontario (CCO): Neoadjuvant and adjuvant systemic therapy for newly diagnosed stage II, III, or IV epithelial ovary, fallopian tube, or primary peritoneal carcinoma (2021)

CCO: Consolidation or maintenance systemic therapy for newly diagnosed stage II, III, or IV epithelial ovary, fallopian tube, or primary peritoneal carcinoma (2020)

CCO: Indications for hyperthermic intraperitoneal chemotherapy with cytoreductive surgery (2019)

CCO: Systemic therapy for recurrent epithelial ovarian cancer (2017)

Society of Gynecologic Oncology of Canada (GOC): Clinical practice guideline – Opportunistic salpingectomy and other methods of risk reduction for ovarian/fallopian tube/peritoneal cancer in the general population (2017)

CCO: Adjuvant care for stage I ovarian cancer (2016)

BC Guidelines: Genital tract cancers in females − Ovarian, fallopian tube, and primary peritoneal cancers (2014)

CCO: PET imaging in ovarian cancer (2009)

United States

National Cancer Institute (NCI): Ovarian epithelial, fallopian tube, and primary peritoneal cancer treatment – Health professional version (2021)

American College of Obstetricians and Gynecologists (ACOG): Committee opinion on opportunistic salpingectomy as a strategy for epithelial ovarian cancer prevention (2019, reaffirmed 2020)

American Society of Clinical Oncology (ASCO): Guideline on germline and somatic tumor testing in epithelial ovarian cancer (2020)

ASCO: Guideline on PARP inhibitors in the management of ovarian cancer (2020)

Chicago Consensus Working Group: Consensus on peritoneal surface malignancies – Management of ovarian neoplasms (2020)

Society of Gynecologic Oncology (SGO): Clinical practice statement – Hormone therapy (HT) in women with gynecologic cancers and in women at high risk for developing a gynecologic cancer (2020)

American College of Radiology (ACR): ACR Appropriateness Criteria on staging and follow-up of ovarian cancer (2018)

SGO: Recommendations on post-treatment surveillance and diagnosis of recurrence in women with gynecologic malignancies, update (2017)

SGO and ASCO: Clinical practice guideline on neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer (2016)

SGO: Clinical practice statement – Genetic testing for ovarian cancer (2014)

Choosing Wisely: Avoid routine imaging for cancer surveillance in women with gynecologic cancer, specifically ovarian, endometrial, cervical, vulvar, and vaginal cancer (2013)

SGO: Clinical practice statement – Salpingectomy for ovarian cancer prevention (2013)

Europe

European experts consensus on BRCA/homologous recombination deficiency testing in first-line ovarian cancer (2022)

European Society of Gynaecological Oncology (ESGO): Guidelines for the peri-operative management of advanced ovarian cancer patients undergoing debulking surgery (2021)

European Society for Medical Oncology (ESMO): Recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer (2020)

ESMO: Relapsed epithelial ovarian carcinoma treatment recommendations, update (2020)

ESMO: Newly diagnosed and relapsed epithelial ovarian carcinoma – Clinical practice guidelines for diagnosis, treatment, and follow-up (2013)

ESMO-ESGO: Consensus conference recommendations on ovarian cancer − Pathology and molecular biology, early and advanced stages, borderline tumours, and recurrent disease (2019)

ESMO: Clinical practice guidelines on non-epithelial ovarian cancer (2018)

ESGO: Guidelines for ovarian cancer surgery (2017)

European Society of Urogenital Radiology (ESUR): Guidelines on ovarian cancer staging and follow-up (2010)

United Kingdom

British Gynaecological Cancer Society (BGCS)/British Association of Gynaecological Pathology (BAGP): Consensus for germline and tumor testing for BRCA1/2 variants in ovarian cancer in the United Kingdom (2021)

National Institute for Health and Care Excellence (NICE): Interventional procedures guidance on cytoreduction surgery with hyperthermic intraoperative peritoneal chemotherapy for peritoneal carcinomatosis (2021)

NICE: Interventional procedures guidance on pressurised intraperitoneal aerosol chemotherapy for peritoneal carcinomatosis (2020)

Scottish Intercollegiate Guidelines Network (SIGN): A national clinical guideline for management of epithelial ovarian cancer (2013, revised 2018)

BGCS: Epithelial ovarian/fallopian tube/primary peritoneal cancer guidelines − Recommendations for practice (2017)

NICE: Interventional procedures guidance on ultra-radical (extensive) surgery for advanced ovarian cancer (2013)

NICE: Quality standard on ovarian cancer (2012)

NICE: Clinical guideline on ovarian cancer − Recognition and initial management (2011)

Australia-New Zealand

Cancer Australia: Position statement on genetic testing for women diagnosed with ovarian cancer (2017)

Cancer Australia: Clinical practice guideline for first-line chemotherapy for the treatment of women with epithelial ovarian cancer (2014)

Japan

[In English] Japan Society of Gynecologic Oncology (JSGO): Guidelines for the treatment of ovarian cancer, fallopian tube cancer, and primary peritoneal cancer, 2020 (published 2021)

[In Japanese] JSGO: Guidelines for the treatment of ovarian cancer, fallopian tube cancer, and primary peritoneal cancer (2020)

Topic 119533 Version 28.0